OPDP not happy with Diclegis promo

Share this article:
OPDP not happy with Diclegis promo
OPDP not happy with Diclegis promo

A prescription morning sickness medication is back on the market for the first time in 30 years, but the honeymoon phase is already over. A letter sent to healthcare providers promoting the drug has captured unwanted attention, and triggered an untitled letter from the Office of Prescription Drug Promotion (OPDP).

The November letter to drug maker Duchesnay, which runs about two-and-three-quarter pages (not including signature lines) is far longer than the promotional item in question, which runs under 200 words (not including greeting and sign-off), a comparison that somewhat amplifies what OPDP finds lacking.

Among regulator's issues with the letter that mentioned the drug's mid-May launch: omission of all risk information associated with the prescription medication that is intended to alleviate pregnancy-related nausea and vomiting. OPDP wrote that failing to include this information in the letter “misleadingly suggests that Diclegis is safer than has been demonstrated.”

OPDP also takes the company to task over the failure to include the full FDA-approved product labeling, as well as providing only the brand name, Diclegis, and not the established name, doxylamine succinate and pyridoxine hydrochloride, as required.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.